The Board of Directors approves the financial statements as of 12/31/2024

THE BOARD OF DIRECTORS OF SVAS BIOSANA APPROVES

THE PRELIMINARY FINANCIAL STATEMENTS AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED AS AT 31 DECEMBER 2024

Double-digit growth in EBIT and Net Profit,

strategic investments and new acquisitions in Eastern Europe Proposed dividend of 0,25 Euro per share

Shareholder's Meeting convened for 20 May 2025 in first call

• Consolidated Revenues : EUR 120.3 million (+1.7% YoY)
• Consolidated1EBITDA: 15.3 million (+7.4% YoY); EBITDA Margin: 12.7%
• Consolidated EBIT: EUR 9.8 million (+14.4% YoY); EBIT Margin 8.1%
• Consolidated Net Income: 5.9 million, an increase of 14.6% on the 2023 financial year
• Cash Group Net Financial Position (NFP) negative for EUR 26.8 million, an improvement over the EUR 27.0 million as of 30 June 2024

1 EBITDA (Earning Before Interest Taxes Depreciations and Amortisations) is the result before financial income and expenses, income taxes, provisions, depreciation and amortisation of fixed assets and impairment of receivables. EBITDA is the indicator used by the Group to monitor and evaluate the operating performance of the business. EBITDA is not identified as an accounting measure under THE Italian Accounting Principles, and therefore should not be considered as an alternative measure for assessing the Group's operating performance. As the composition of EBITDA is not regulated by the relevant accounting standards, the determination criteria applied by the Group may not be homogeneous with those adopted by other entities, and therefore may not be comparable with them.

SVAS' desire to grow sustainably by focusing on quality, specialisation and service. We look to the future with confidence, aware of the increasingly strategic role we are called upon to play in the health sector."

In 2024, Svas Biosana continued its growth path, in a context in which the National Health Service has been working steadily and intensified its investments in medical technologies thanks to PNRR funds. Demand for advanced and specialised devices remained buoyant, fostering the technical and commercial development of the company's most innovative lines. Particularly noteworthy were the results of the production line dedicated to adult incontinence products, which ensured higher volumes and high product quality, helping contain the effects of the continuing increase in raw material costs. Despite the still challenging inflationary environment, the company has strengthened its management and logistics systems, reinforcing its ability to operate extensively and efficiently. The year 2024 is thus confirmed as a good year for Svas Biosana and the entire health sector, which has returned to work with a long-term perspective.

Reclassified Consolidated Income Statement

Group data summary

EBIT (operating profit) amounted to Euro 9.8 million, an increase of 14.4% compared to Euro 8.6 million on 31 December 2023, with an EBIT margin of 8.1% on revenue.

As of 30 June 2024, the Net Financial Position was cash negative in the amount of Euro 26.8 million, compared to the cash negative NFP of Euro 27.0 million.

Shareholders' equity amounted to Euro 62.8 million, an increase of Euro 3.8 million compared to Euro 59.0 million on 31 December 2023.

Ultimate Parent Company Financial Statements

EBIT (Operating Profit) amounted to Euro 2.1 million, in line with the value as of 31 December 2023 and with an EBIT margin of 3.8% on revenue.

The Net Profit was positive at Euro 1.1 million, essentially unchanged from the year 2023.

The Net Financial Position is cash negative and amounted to Euro 25.5 million compared to the cash negative NFP of Euro 23.1 million on 31 December 2023.

In relation to the results achieved, the Board of Directors resolved to propose to the Shareholders' Meeting to allocate the profit of Euro 1,138,146 as follows:

1. Euro 56,907 to the legal reserve.

2. and the remainder as a dividend together with a portion of the Extraordinary Reserve, distributing an ordinary gross dividend equal to Euro 0.25 per share in circulation on the ex-dividend date (net of the treasury shares that will be in the portfolio on that date) according to the following dates:

   • ex-dividend date 9 June 2025

   • record date: 10 June 2025

   • payment date: 11 June 2025

• On 18 October 2024, the Company resolved to issue a non-convertible, non-subordinated debenture loan, pursuant to Article 2410 of the Italian Civil Code and Article 1, paragraph 1 bis, of Law No. 130 of 30 April 1999, for a nominal amount of EUR 6 million, to support the Company's investment and growth plan.

  SVAS BIOSANA S.p.A.	Sede Legale	Corrispondenza	Direzione ed Uffici	Contatti
  Registro Imprese di	Via M. Perillo, 34	Casella Postale n.91	Via Trentola, 7	Tel. +390818995411
  Napoli n.4543/85	80047	80049	80049	Fax +390818993922
  n. R.E.A. 393065	San Giuseppe Vesuviano (NA)	Somma Vesuviana (NA)	Somma Vesuviana (NA)	https://www.svas.it
  C.F. 04720630633	Italy	Italy	Italy	svasbiosana@legalmail.it

• On 15 November 2024, the treasury shares purchase programme that started on 22 May 2023 ended in accordance with the terms and conditions of the authorisation resolution approved by the Shareholders' Meeting on 16 May 2023. The purchases were realised under the coordination of Banca Profilo S.p.A. In the period between 22 May 2023 and 15 November 2024 (inclusive), the Company purchased a total of 75,501 treasury shares (equal to 1.3482% of the share capital) for a total value of EUR 589,005.93.

• On 23 December 2024, Mark Medical S.p.A. (a wholly owned subsidiary of Svas Biosana S.p.A) signed the binding agreement to acquire 100% of the Hermes Pharma D.o.o. share capital for EUR 3.5 million plus a variable earn-out of approximately EUR 250 thousand. The closing of the transaction took place on 10 March 2025.

• On 27 December 2024, the Shareholders' Meeting granted the Board of Directors the authorisation to purchase and dispose of treasury shares for a period of 18 months, in one or more instalments, up to a maximum of 20% of the Company's share capital, pursuant to Article 25-bis of the Euronext Growth Milan Issuers' Regulations or any different maximum amount provided for by the regulations in force. The maximum consideration approved shall not exceed Euro 1,000,000. The Purchase Programme was initiated by resolution of the Board of Directors on 27 December 2024.

• On 30 December 2024 the company Levante HC Holding D.o.o. (a wholly owned subsidiary of Svas Biosana S.p.A) signed the binding agreement to acquire 100% of the share capital of Megapharm

  D.o.o. Beograd for a consideration of EUR 3.0 million plus an earn-out of approximately EUR 250 thousand. The closing of the transaction was finalised on 10 March 2025.

  SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

• On 10 March 2025, the conditions precedent stipulated in the contracts having been fulfilled, the transactions for the acquisition of the company Hermes Pharma D.o.o. by Mark Medical S.p.A. (a wholly owned subsidiary of Svas Biosana S.p.A.) and of the company Megapharm D.o.o. by Levante HC Holding D.o.o. (a wholly owned subsidiary of Svas Biosana S.p.A.) were finalised.

  OUTLOOK

  The international macroeconomic environment continues to present elements of high uncertainty, linked to the evolution of ongoing conflicts - particularly between Russia and Ukraine and in the Middle East - as well as future monetary policy decisions by the Federal Reserve and the European Central Bank. Further important variables concern the direction of US trade policy, which is currently characterised by developments that are difficult to interpret and are unpredictable.

  It is hoped that geopolitical tensions will have a limited and temporary impact, without compromising the stability of global supply chains and overall macroeconomic balances.

  The Board of Directors reports that these factors did not have a negative impact on the economic and equity valuations of the financial statements subject to approval, nor in the first months of 2025.

  In this scenario, the Company confirms its willingness to continue its growth path, both on the commercial and industrial fronts.

  SVAS BIOSANA S.p.A.	Sede Legale	Corrispondenza	Direzione ed Uffici	Contatti
  Registro Imprese di	Via M. Perillo, 34	Casella Postale n.91	Via Trentola, 7	Tel. +390818995411
  Napoli n.4543/85	80047	80049	80049	Fax +390818993922
  n. R.E.A. 393065	San Giuseppe Vesuviano (NA)	Somma Vesuviana (NA)	Somma Vesuviana (NA)	https://www.svas.it
  C.F. 04720630633	Italy	Italy	Italy	svasbiosana@legalmail.it

  OTHER BOARD OF DIRECTORS RESOLUTIONS

• The Board of Directors ascertained the continued existence of the independence requirements of director Antonio Finocchi Ghersi pursuant to the combined provisions of Articles 147-ter and 148, par. 3 of Legislative Decree 24 February 1998, as well as pursuant to Article 21 of the Articles of Association. The Board of Directors assessed the existence of the requirements on the basis of the information provided by Antonio Finocchi Ghersi, as well as on the basis of the public information available or otherwise at the Company's disposal.

• The Board of Directors also approved the adoption of the Organisation, Management and Control Model pursuant to Legislative Decree No. 231/2001 and the Code of Ethics, in updated versions, and approved the updating of the internal dealing procedure.

The Board of Directors has resolved to convene the Ordinary Shareholders Meeting on 20 May 2025, on first call, and, if necessary, on 21 May 2025, on second call, at the times and places to be communicated in the meeting notice to be published in accordance with the procedures and terms of law and the Articles of Association, to discuss and resolve on the approval of the Financial Statements for the year ended 31.12.2024, the presentation of the Consolidated Financial Statements as at 31.12.2024 and the allocation of the profit for the year and distribution of the dividend.

The Notice of Shareholders' Meeting will also indicate the terms of participation in the meeting in accordance with the regulations in force.

* * * * * *

The annual financial report including the draft financial statements and the consolidated financial statements, the reports on operations, the reports of the independent auditors and the reports of the Board of Statutory Auditors will be made available to the public, within the terms provided by law, at the Company's registered office and on the website https://www.svas.it under the Investor Relations/Financial Statements and Reports section, at Borsa Italiana and on the eMarket SDIR (https://www.emarketstorage.com) storage mechanism within the terms provided by the regulations in force. Further necessary documents and information relating to the shareholders meeting will also be made available on the Company's website.

* * * * * *

We would like to inform you that the audit of the draft financial statements and the consolidated financial statements as of 31 December 2024 has not yet been completed and that the auditors' reports will therefore be made available within the legal deadlines. Finally, it should be noted that the attached profit and loss accounts and balance sheets are reclassified and, as such, are not subject to audit.

* * * * * *